Viewing Study NCT02164461


Ignite Creation Date: 2025-12-24 @ 1:03 PM
Ignite Modification Date: 2026-02-20 @ 1:43 PM
Study NCT ID: NCT02164461
Status: COMPLETED
Last Update Posted: 2024-05-20
First Post: 2014-06-13
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Sponsor: Advaxis, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Effects of Immunotherapy View
None Metastatic/Recurrent Cervical Cancer View
None Cervical Adenocarcinoma View
None Cervical Adenosquamous Cell Carcinoma View
None Cervical Squamous Cell Carcinoma View
None Cervical Small Cell Carcinoma View
None Stage III Cervical Cancer View
None Stage IVA Cervical Cancer View
None Stage IVB Cervical Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Adenocarcinoma View
None Carcinoma View
None Carcinoma, Squamous Cell View
None Uterine Cervical Neoplasms View
None Small Cell Lung Carcinoma View
None Carcinoma, Small Cell View
None Carcinoma, Adenosquamous View
None Neoplasms, Glandular and Epithelial View
None Neoplasms by Histologic Type View
None Neoplasms View
None Neoplasms, Squamous Cell View
None Uterine Neoplasms View
None Genital Neoplasms, Female View
None Urogenital Neoplasms View
None Neoplasms by Site View
None Uterine Cervical Diseases View
None Uterine Diseases View
None Genital Diseases, Female View